As Shares, Revenues Continue to Dive Nuvelo Struggles to Sell Its PGx Assets | GenomeWeb

Shares in Nuvelo have fallen more than 15 percent over the past four days as many investors expressed doubt the nascent drug maker can sustain plummeting revenues and widening net losses long enough to bring a single compound to market. Additionally, questions linger about the pharmacogenomics assets the company appears not to have sold yet.

Nuvelo, which was created when Hyseq acquired Variagenics in January 2003, has been plagued by sharply falling revenues, most recently in the first quarter, as it continues to develop its three drug candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.